Not Yet RecruitingPhase 2

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

115 participantsStarted 2025-07-08

Plain-language summary

A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the informed consent form;
✓. At the time of screening, the age should be between 18 and 75 years old (inclusive), regardless of gender;

Exclusion criteria

✕. At the time of enrollment, the expected survival time is more than 6 Months;
✕. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;
✕. At the time of screening, the laboratory tests should meet the following requirements:
✕. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and be willing to use medically recognized highly effective contraception during the study and for at least 1 year after the last study treatment; male subjects with partners of childbearing potential must have undergone surgical sterilization or agree to use effective contraception during the study and for at least 1 year after the last study treatment;
✕. Investigator-confirmed eligibility for study enrollment.
✕. NSCLC patients who have received neoadjuvant therapy;
✕. Pregnant or lactating women;
✕. History of other malignancies, except:

What they're measuring

Incidence and severity of adverse events (AEs)

Timeframe: 3 months

Disease Free Surviva Percentage（DFS%）

Timeframe: 1 year

Trial details

NCT IDNCT07043907

SponsorShenzhen Celconta Life Science Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-07-08

Contact for this trial

Shuanghu Yuan

0551-65897870 yuanshuanghu@sina.com

View on ClinicalTrials.gov More Stage IIIA Non-small Cell Lung Cancer trials